Next 10 |
2024-06-03 08:19:09 ET More on aTyr Pharma aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on aTyr Pharma Historical earnings data for aTyr Pharma Financial information for aTyr Pharma Read the full arti...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
2024-05-19 06:35:40 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...
2024-05-02 17:34:16 ET More on aTyr Pharma aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on aTyr Pharma Historical earnings data for aTyr Pharma Financial information for aTyr Pharma Read the full arti...
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, May 02, 2024 (GLOBE NEWS...
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcom...
2024-03-26 14:19:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we’re done here, right? Of course, human nature being what it is, people are ...
2024-03-19 08:04:18 ET More on premarkets gainers & stock I Worry That WW International, Formerly Weight Watchers, May Not Survive WW International, Inc. (WW) Q4 2023 Earnings Call Transcript Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upg...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...